X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-10-01 | SYRE | Spyre Therapeutics, Inc. | King-Jones Heidy | See Remarks | S - Sale+OE | $91.03 | -28,933 | 2,845 | -91% | -$2,633,902 | |||||
2026-10-01 | SYRE | Spyre Therapeutics, Inc. | Turtle Cameron | CEO | S - Sale | $92.01 | -15,000 | 537,540 | -3% | -$1,380,105 | ||||||
| DM | 2026-09-30 | SYRE | Spyre Therapeutics, Inc. | Burrows Scott L | CFO | S - Sale+OE | $90.47 | -25,000 | 79,762 | -24% | -$2,261,831 | |||||
| D | 2026-10-01 | ORKA | Oruka Therapeutics, Inc. | Klein Lawrence Otto | CEO | S - Sale+OE | $83.62 | -25,000 | 923,128 | -3% | -$2,090,593 | |||||
2026-09-30 | IRD | Opus Genetics, Inc. | Foundation Fighting Blindness Retinal Degeneration Fund | See Remarks | S - Sale | $4.96 | -556,000 | 3,236,171 | -15% | -$2,755,981 | ||||||
2026-10-02 | ALKS | Alkermes Plc. | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | S - Sale | $41.03 | -2,034 | 221,388 | -1% | -$83,455 | ||||||
2026-09-30 | MLYS | Mineralys Therapeutics, Inc. | Congleton Jon | CEO | S - Sale | $25.46 | -75,000 | 528,621 | -12% | -$1,909,665 | ||||||
| D | 2026-10-01 | ORIC | Oric Pharmaceuticals, Inc. | Heyman Richard A. | Dir | S - Sale+OE | $12.91 | -6,700 | 241,772 | -3% | -$86,524 | |||||
| D | 2026-10-01 | ANAB | Anaptysbio, Inc | Renton Hollings | Dir | S - Sale+OE | $49.87 | -5,000 | 10,995 | -31% | -$249,372 | |||||
| D | 2026-09-30 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $36.62 | -200,000 | 1,599,154 | -11% | -$7,324,000 | |||||
2026-10-02 | STOK | Stoke Therapeutics, Inc. | Allan Jonathan | GC, Corp Sec | S - Sale | $26.33 | -627 | 20,598 | -3% | -$16,509 | ||||||
2026-10-01 | STOK | Stoke Therapeutics, Inc. | Ticho Barry | Chief Medical Officer | S - Sale | $26.16 | -1,051 | 19,059 | -5% | -$27,494 | ||||||
| D | 2026-10-02 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | GC | S - Sale+OE | $23.19 | -5,786 | 9,110 | -39% | -$134,149 | |||||
| D | 2026-09-30 | PTCT | Ptc Therapeutics, Inc. | Steele Glenn Jr Md Phd | Dir | S - Sale+OE | $65.16 | -12,000 | 22,500 | -35% | -$781,920 | |||||
2026-10-01 | ORMP | Oramed Pharmaceuticals Inc. | Gabay Avraham | CFO | S - Sale | $4.51 | -20,000 | 861,076 | -2% | -$90,200 | ||||||
2026-10-01 | ORMP | Oramed Pharmaceuticals Inc. | Hexter Joshua | COO, CBO | S - Sale | $4.51 | -30,000 | 1,328,130 | -2% | -$135,330 | ||||||
2026-10-01 | VSTM | Verastem, Inc. | Paterson Dan | Pres, CEO | S - Sale | $8.00 | -44,121 | 652,712 | -6% | -$352,968 | ||||||
2026-10-01 | VSTM | Verastem, Inc. | Calkins Daniel | CFO | S - Sale | $8.00 | -2,566 | 123,781 | -2% | -$20,528 | ||||||
2026-10-01 | XERS | Xeris Biopharma Holdings, Inc. | Pieper Steven | See Remarks | S - Sale | $9.41 | -5,000 | 1,351,053 | 0% | -$47,037 | ||||||
2026-10-01 | XERS | Xeris Biopharma Holdings, Inc. | McCulloch Kevin | See Remarks | S - Sale | $9.41 | -15,000 | 1,624,208 | -1% | -$141,120 | ||||||
2026-10-01 | XERS | Xeris Biopharma Holdings, Inc. | Hecht Beth | See Remarks | S - Sale | $9.41 | -16,666 | 1,111,130 | -1% | -$156,792 | ||||||
2026-09-30 | ONC | Beone Medicines Ltd. | Lee Chan Henry | SVP, GC | S - Sale | $375.00 | -1,115 | 311,324 | 0% | -$418,125 | ||||||
| D | 2026-10-01 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $576.47 | -9,500 | 668,728 | -1% | -$5,476,462 | |||||
| D | 2026-09-30 | NAMS | Newamsterdam Pharma Co N.V. | Kastelein Johannes Jacob Pieter | Chief Scientific Officer | S - Sale+OE | $25.03 | -50,246 | 122,802 | -29% | -$1,257,657 | |||||
| D | 2026-09-29 | HEPA | Hepion Pharmaceuticals, Inc. | Fisher Danina | Dir | P - Purchase | $0.05 | +200,000 | 200,000 | New | +$10,000 | |||||
| D | 2026-09-30 | PTGX | Protagonist Therapeutics, Inc | Ali Asif | CFO | S - Sale+OE | $141.78 | -58,629 | 59,003 | -50% | -$8,312,294 | |||||
2026-10-01 | KPTI | Karyopharm Therapeutics Inc. | Abate Kristin | Chief Accounting Officer | S - Sale | $1.19 | -378 | 23,404 | -2% | -$450 | ||||||
| D | 2026-10-01 | PYXS | Pyxis Oncology, Inc. | Gordonmd Global Investments LP | 10% | P - Purchase | $0.00 | +5,517,000 | 15,541,909 | +55% | +$0 | |||||
| DM | 2026-09-29 | ANRO | Alto Neuroscience, Inc. | Smith Nicholas Conrad | Pres, CFO | S - Sale+OE | $26.45 | -134,886 | 24,060 | -85% | -$3,567,247 | |||||
| M | 2026-09-29 | LPCN | Lipocine Inc. | Higuchi John W. | Dir | P - Purchase | $2.20 | +25,007 | 241,365 | +12% | +$55,043 | |||||
2026-09-29 | HELP | Helus Pharma Inc. | Cavers Greg | CFO | P - Purchase | $12.91 | +3,000 | 128,937 | +2% | +$38,730 | ||||||
| D | 2026-10-01 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $564.95 | -8,300 | 45,172 | -16% | -$4,689,051 | |||||
2026-09-30 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale | $550.22 | -1,920 | 668,728 | 0% | -$1,056,425 | ||||||
| D | 2026-09-30 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $517.97 | -7,580 | 670,648 | -1% | -$3,926,177 | |||||
2026-09-29 | GRCE | Grace Therapeutics, Inc. | Opaleye Management Inc. | 10% | P - Purchase | $2.09 | +7,849 | 2,798,167 | 0% | +$16,404 | ||||||
2026-09-30 | RAPP | Rapport Therapeutics, Inc. | Gault Cheryl | COO | S - Sale | $33.19 | -10,000 | 139,914 | -7% | -$331,856 | ||||||
| AM | 2026-09-21 | GRCE | Grace Therapeutics, Inc. | Opaleye Management Inc. | 10% | P - Purchase | $2.10 | +15,089 | 2,790,318 | +1% | +$31,687 | |||||
2026-09-29 | LEGN | Legend Biotech Corp | Sanders Corazon (Corsee) D. | Dir | S - Sale | $9.46 | -27,370 | 52,731 | -34% | -$258,920 | ||||||
| M | 2026-09-29 | ANL | Adlai Nortye Group Ltd. | Ji Ping | Dir | S - Sale | $15.99 | -10,214 | 121,453 | -8% | -$163,275 | |||||
2026-09-30 | XENE | Xenon Pharmaceuticals Inc. | Kelly Thomas Patrick | CFO | P - Purchase | $37.32 | +15,000 | 15,000 | New | +$559,740 | ||||||
2026-09-30 | XENE | Xenon Pharmaceuticals Inc. | Mortimer Ian | Pres, CEO | P - Purchase | $37.38 | +30,000 | 64,223 | +88% | +$1,121,400 | ||||||
| M | 2026-09-29 | FLNA | Filana Therapeutics, Inc. | Barry Richard | Pres, CEO | P - Purchase | $0.91 | +306,813 | 1,337,964 | +30% | +$278,132 | |||||
2026-09-28 | LPCN | Lipocine Inc. | Higuchi John W. | Dir | P - Purchase | $2.16 | +12,561 | 216,358 | +6% | +$27,132 | ||||||
| D | 2026-09-28 | ADRX | Adarx Pharmaceuticals, Inc. | Chimovits Erez | Dir | P - Purchase | $17.00 | +61,516 | 9,292,025 | +1% | +$1,045,772 | |||||
| D | 2026-09-28 | ADRX | Adarx Pharmaceuticals, Inc. | Gordon Carl L | Dir, 10% | P - Purchase | $17.00 | +950,000 | 588,235 | -263% | +$16,150,000 | |||||
| D | 2026-09-28 | ADRX | Adarx Pharmaceuticals, Inc. | Orbimed Advisors LLC | Dir, 10% | P - Purchase | $17.00 | +950,000 | 588,235 | -263% | +$16,150,000 | |||||
| D | 2026-09-28 | ONC | Beone Medicines Ltd. | Wang Xiaodong | Chair, Scientific Advisory Brd | S - Sale+OE | $364.79 | -31,028 | 9,566,326 | 0% | -$11,318,558 | |||||
2026-09-29 | PRTA | Prothena Corp Public Ltd Co | Scully William P | 10% | P - Purchase | $8.68 | +162,000 | 1,328,000 | +14% | +$1,405,674 | ||||||
2026-09-29 | ANIP | Ani Pharmaceuticals Inc | Carey Stephen P. | SVP, CFO | S - Sale | $73.00 | -2,850 | 168,993 | -2% | -$208,050 | ||||||
2026-09-28 | RPRX | Royalty Pharma Plc | Urist Marshall | EVP, Research, Investments | S - Sale | $57.88 | -4,126 | 23,146 | -15% | -$238,813 | ||||||
| D | 2026-09-29 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $477.42 | -9,500 | 668,728 | -1% | -$4,535,480 | |||||
2026-09-28 | FLNA | Filana Therapeutics, Inc. | Barry Richard | Pres, CEO | P - Purchase | $0.84 | +93,091 | 1,031,151 | +10% | +$78,196 | ||||||
| M | 2026-09-28 | PHIO | Phio Pharmaceuticals Corp. | Plott Ronald Todd | Dir | P - Purchase | $1.04 | +10,000 | 42,000 | +31% | +$10,350 | |||||
2026-09-30 | ANIX | Anixa Biosciences Inc | Catelani Michael | Pres, COO, CFO | P - Purchase | $2.84 | +5,500 | 50,000 | +12% | +$15,620 | ||||||
2026-09-29 | ABEO | Abeona Therapeutics Inc. | Seshadri Vishwas | CEO | S - Sale | $5.16 | -19,608 | 1,286,500 | -2% | -$101,091 | ||||||
2026-09-29 | ABEO | Abeona Therapeutics Inc. | Vazzano Joseph Walter | CFO | S - Sale | $5.16 | -9,191 | 482,888 | -2% | -$47,385 | ||||||
2026-09-29 | ABEO | Abeona Therapeutics Inc. | O'Malley Brendan M. | SVP, GC | S - Sale | $5.16 | -6,727 | 421,226 | -2% | -$34,682 | ||||||
2026-09-29 | ABEO | Abeona Therapeutics Inc. | Vasanthavada Madhav | Chief Commercial Officer | S - Sale | $5.16 | -4,902 | 285,721 | -2% | -$25,273 | ||||||
| D | 2026-09-28 | ADRX | Adarx Pharmaceuticals, Inc. | Sr One Capital Management, LLC | 10% | P - Purchase | $17.00 | +1,600,000 | 9,936,661 | +19% | +$27,200,000 | |||||
| D | 2026-09-28 | ADRX | Adarx Pharmaceuticals, Inc. | George Simeon | Dir, 10% | P - Purchase | $17.00 | +1,600,000 | 9,936,661 | +19% | +$27,200,000 | |||||
| D | 2026-09-28 | ORIC | Oric Pharmaceuticals, Inc. | Piscitelli Dominic | CFO | S - Sale+OE | $13.53 | -13,400 | 69,828 | -16% | -$181,258 | |||||
2026-09-28 | KURA | Kura Oncology, Inc. | Bair Teresa Brophy | GC | S - Sale | $10.50 | -8,442 | 187,002 | -4% | -$88,618 | ||||||
| M | 2026-09-28 | KURA | Kura Oncology, Inc. | Ford Kathleen | COO | S - Sale | $10.59 | -10,574 | 142,986 | -7% | -$111,931 | |||||
| M | 2026-09-28 | KURA | Kura Oncology, Inc. | Leoni Mollie | Chief Medical Officer | S - Sale | $10.67 | -41,250 | 141,095 | -23% | -$440,237 | |||||
2026-09-28 | KURA | Kura Oncology, Inc. | Doyle Thomas James | SVP, Finance, Accounting | S - Sale | $10.50 | -4,607 | 142,928 | -3% | -$48,361 | ||||||
| M | 2026-09-28 | KURA | Kura Oncology, Inc. | Powl Brian T. | Chief Commercial Officer | S - Sale | $10.63 | -32,450 | 136,819 | -19% | -$345,036 | |||||
2026-09-28 | PRTA | Prothena Corp Public Ltd Co | Scully William P | 10% | P - Purchase | $8.60 | +103,500 | 1,166,000 | +10% | +$889,872 | ||||||
2026-09-25 | MNOV | Medicinova Inc | 3D Investment Partners Pte. Ltd. | Formerly 10% Owner | S - Sale | $2.70 | -640,000 | 4,862,047 | -12% | -$1,728,000 | ||||||
2026-09-28 | XERS | Xeris Biopharma Holdings, Inc. | McCulloch Kevin | See Remarks | S - Sale | $10.00 | -25,000 | 1,639,208 | -2% | -$250,000 | ||||||
| D | 2026-09-28 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $480.85 | -9,500 | 668,728 | -1% | -$4,568,106 | |||||
2026-09-10 | VRXA | Veraxa Biotech AG | Hosseinion Warren | Dir | P - Purchase | $1.67 | +6,024 | 634,692 | +1% | +$10,060 | ||||||
| A | 2026-09-22 | CTTH | Ctt Pharmaceutical Holdings, Inc. | Ctt Pharmaceutical Holdings, Inc. | CEO | P - Purchase | $0.05 | +10,100 | 9,424,556 | 0% | +$455 | |||||
| D | 2026-09-24 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO | S - Sale+OE | $88.00 | -29,056 | 162,082 | -15% | -$2,556,851 | |||||
2026-09-25 | MNKD | Mannkind Corp | Binder Steven B. | Dir | S - Sale | $3.29 | -39,051 | 713,258 | -5% | -$128,478 | ||||||
| D | 2026-09-28 | CYTK | Cytokinetics Inc | Blum Robert I | Pres, CEO | S - Sale+OE | $65.46 | -7,500 | 282,710 | -3% | -$490,950 | |||||
| D | 2026-09-25 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $476.17 | -9,500 | 668,728 | -1% | -$4,523,635 | |||||
2026-09-28 | CTTH | Ctt Pharmaceutical Holdings, Inc. | Ctt Pharmaceutical Holdings, Inc. | CEO | P - Purchase | $0.06 | +3,400 | 9,429,956 | 0% | +$187 | ||||||
2026-09-24 | ANIX | Anixa Biosciences Inc | Kumar Amit | CEO | P - Purchase | $2.78 | +7,000 | 672,000 | +1% | +$19,460 | ||||||
2026-09-24 | ANIX | Anixa Biosciences Inc | Baskies Arnold M | Dir | P - Purchase | $2.76 | +5,000 | 140,572 | +4% | +$13,800 | ||||||
2026-09-25 | DMRA | Damora Therapeutics, Inc. | Jarrett Jennifer | Dir, Pres, CEO | P - Purchase | $20.23 | +12,500 | 512,500 | +3% | +$252,875 | ||||||
| D | 2026-09-24 | ORIC | Oric Pharmaceuticals, Inc. | Piscitelli Dominic | CFO | S - Sale+OE | $13.50 | -600 | 69,828 | -1% | -$8,103 | |||||
2026-09-23 | ADAG | Adagene Inc. | Tam Man Kin | CFO | P - Purchase | $3.00 | +2,000 | 37,000 | +6% | +$6,000 | ||||||
2026-09-25 | CYPH | Cypherpunk Technologies Inc. | Oei Khing Djien | Dir | S - Sale | $3.92 | -168,750 | 0 | -100% | -$661,500 | ||||||
2026-09-23 | CYPH | Cypherpunk Technologies Inc. | Martin Patricia A. | Dir | S - Sale | $3.86 | -50,000 | 118,750 | -30% | -$193,000 | ||||||
| D | 2026-09-24 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $473.55 | -9,500 | 668,728 | -1% | -$4,498,753 | |||||
2026-09-24 | ANNX | Annexon, Inc. | Love Douglas | Pres, CEO | P - Purchase | $3.83 | +26,065 | 390,476 | +7% | +$99,829 | ||||||
| D | 2026-09-24 | KURA | Kura Oncology, Inc. | Burrows Francis | Chief Scientific Officer | S - Sale+OE | $10.83 | -20,726 | 42,327 | -33% | -$224,514 | |||||
2026-09-24 | PHIO | Phio Pharmaceuticals Corp. | Bradford Patricia A | Dir | P - Purchase | $1.01 | +6,500 | 64,151 | +11% | +$6,583 | ||||||
| D | 2026-09-23 | PHVS | Pharvaris N.V. | Monges Viviane | Dir | S - Sale+OE | $33.05 | -11,969 | 5,500 | -69% | -$395,524 | |||||
2026-09-23 | ANIX | Anixa Biosciences Inc | Titterton Lewis H Jr | Dir | P - Purchase | $2.69 | +49,036 | 1,046,003 | +5% | +$131,907 | ||||||
2026-09-22 | MLYS | Mineralys Therapeutics, Inc. | Slingsby Brian Taylor | Dir | S - Sale | $28.81 | -104,320 | 7,805,718 | -1% | -$3,005,303 | ||||||
| DM | 2026-09-22 | OMER | Omeros Corp | Borges David J. | VP, Finance, CAO | S - Sale+OE | $20.95 | -20,000 | 0 | -100% | -$419,000 | |||||
2026-09-22 | TNGX | Tango Therapeutics, Inc. | Newcomb Jessica | Principal Accounting Officer | S - Sale | $24.22 | -8,200 | 59,121 | -12% | -$198,613 | ||||||
| M | 2026-09-22 | SKYE | Skye Bioscience, Inc. | Schwab Andrew J. | Dir, 10% | S - Sale | $1.62 | -148,079 | 981,269 | -13% | -$239,555 | |||||
| D | 2026-09-23 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $491.57 | -9,500 | 668,728 | -1% | -$4,669,918 | |||||
| M | 2026-09-22 | SKYE | Skye Bioscience, Inc. | 5Am Partners Vii, LLC | 10% | S - Sale | $1.62 | -148,079 | 981,269 | -13% | -$239,555 | |||||
2026-09-22 | RPRX | Royalty Pharma Plc | Hite Christopher | EVP, COB, Partnering | S - Sale | $58.53 | -100,000 | 293,601 | -25% | -$5,853,095 | ||||||
2026-09-23 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | CEO | S - Sale | $39.17 | -2,210 | 559,225 | 0% | -$86,565 | ||||||
| D | 2026-09-23 | AKTS | Aktis Oncology, Inc. | Czibere Akos | Chief Medical Officer | S - Sale+OE | $20.69 | -12,500 | 0 | -100% | -$258,621 | |||||
2026-09-22 | ANL | Adlai Nortye Group Ltd. | Ji Ping | Dir | S - Sale | $16.63 | -5,000 | 131,667 | -4% | -$83,150 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |